{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:15:09Z","timestamp":1791918909175,"version":"4.3.4"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.addr.2022.114613","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T12:37:11Z","timestamp":1667565431000},"page":"114613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Design, development and clinical translation of CriPec\u00ae-based core-crosslinked polymeric micelles"],"prefix":"10.1016","volume":"191","author":[{"given":"Cristianne J.F.","family":"Rijcken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"De Lorenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Biancacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob G.J.M.","family":"Hanssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Thewissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Atrafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob M.J.","family":"Liskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris H.C.","family":"Miedema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Willemien","family":"Menke - van der Houven van Oordt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guus A.M.S.","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle J.","family":"Vugts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim E.","family":"Hennink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1090-6805","authenticated-orcid":false,"given":"Twan","family":"Lammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2022.114613_b0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114613_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.100853","article-title":"The success of nanomedicine","volume":"31","author":"Lammers","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.addr.2022.114613_b0015","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2022.114613_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2022.114613_b0025","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2022.114613_b0030","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2022.114613_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/smll.202103025","article-title":"Modular lipid nanoparticle platform technology for siRNA and lipophilic prodrug delivery","volume":"17","author":"van der Meel","year":"2021","journal-title":"Small"},{"key":"10.1016\/j.addr.2022.114613_b0040","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114613_b0045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114613_b0050","doi-asserted-by":"crossref","unstructured":"R. Van Der Meel, T. Lammers, W.E. Hennink, Expert Opinion on Drug Delivery Cancer nanomedicines: oversold or underappreciated? Cancer nanomedicines: oversold or underappreciated?, (2016). 10.1080\/17425247.2017.1262346.","DOI":"10.1080\/17425247.2017.1262346"},{"key":"10.1016\/j.addr.2022.114613_b0055","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.chembiol.2017.06.012","article-title":"Tumor organoids as a pre-clinical cancer model for drug discovery","volume":"24","author":"Weeber","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.addr.2022.114613_b0060","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.addr.2021.03.018","article-title":"The past, present, and future of breast cancer models for nanomedicine development","volume":"173","author":"Boix-Montesinos","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114613_b0065","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/IJN.S129300","article-title":"Protein corona: a new approach for nanomedicine design","volume":"12","author":"Nguyen","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2022.114613_b0070","unstructured":"J.Y. Oh, H.S. Kim, L. Palanikumar, E.M. Go, B. Jana, S.A. Park, H.Y. Kim, K. Kim, J. Kon Seo, S.K. Kwak, C. Kim, S. Kang, J.-H. Ryu, Cloaking nanoparticles with protein corona shield for targeted drug delivery, (n.d.). 10.1038\/s41467-018-06979-4."},{"key":"10.1016\/j.addr.2022.114613_b0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2022.114613_b0080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1039\/C8CS00473K","article-title":"Nanomedicine and macroscale materials in immuno-oncology","volume":"48","author":"Sun","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2022.114613_b0085","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.smim.2017.09.007","article-title":"Modulating the immune system through nanotechnology","volume":"34","author":"Dacoba","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.addr.2022.114613_b0090","unstructured":"F. Dewez, M. Martin-Lorenzo, M. Herfs, D. Baiwir, G. Mazzucchelli, E. De Pauw, R.M.A. Heeren, B. Balluff, Precise co-registration of mass spectrometry imaging, histology, and laser microdissection-based omics, (n.d.). 10.1007\/s00216-019-01983-z."},{"key":"10.1016\/j.addr.2022.114613_b0095","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/bs.acr.2016.11.008","article-title":"Mass spectrometry imaging for the investigation of intratumor heterogeneity","volume":"134","author":"Balluff","year":"2017","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.addr.2022.114613_b0100","doi-asserted-by":"crossref","first-page":"e10246","DOI":"10.1002\/btm2.10246","article-title":"Nanoparticles in the clinic: an update post COVID-19 vaccines","volume":"6","author":"Anselmo","year":"2021","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.addr.2022.114613_b0105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jconrel.2020.07.007","article-title":"Delivering the power of nanomedicine to patients today","volume":"326","author":"Germain","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114613_b0110","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM\/Doxil\u00ae) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2022.114613_b0115","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114613_b0120","first-page":"624","article-title":"Photodynamic therapy with Verteporfin (Visudyne): impact on ophthalmology and visual sciences","volume":"41","author":"Bressler","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114613_b0125","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia","volume":"25","author":"Krauss","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2022.114613_b0130","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1021\/acs.molpharmaceut.7b00188","article-title":"Overcoming the road blocks: advancement of block copolymer micelles for cancer therapy in the clinic","volume":"14","author":"Houdaihed","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2022.114613_b0135","doi-asserted-by":"crossref","unstructured":"H. Cabral, K. Miyata, K. Osada, K. Kataoka, Block Copolymer Micelles in Nanomedicine Applications, (2018). 10.1021\/acs.chemrev.8b00199.","DOI":"10.1021\/acs.chemrev.8b00199"},{"key":"10.1016\/j.addr.2022.114613_b0140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nantod.2015.01.005","article-title":"Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation","volume":"10","author":"Talelli","year":"2015","journal-title":"Nano Today"},{"key":"10.1016\/j.addr.2022.114613_b0145","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cell.2020.02.001","article-title":"Targeting strategies for tissue-specific drug delivery","volume":"181","author":"Zhao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2022.114613_b0150","doi-asserted-by":"crossref","unstructured":"J. Reshma, G. Jinu, J. Franklin, Brief Outlook on Polymeric Nanoparticles, Micelles, Niosomes, Hydrogels and Liposomes: Preparative Methods and Action, ChemistrySelect. 7 (2022) e202104045.","DOI":"10.1002\/slct.202104045"},{"key":"10.1016\/j.addr.2022.114613_b0155","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.addr.2009.11.029","article-title":"Micelles based on HPMA copolymers","volume":"62","author":"Talelli","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114613_b0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2012.09.013","article-title":"Block copolymer micelles for drug delivery: Design, characterization and biological significance","volume":"64","author":"Kataoka","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114613_b0165","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jconrel.2014.06.042","article-title":"Progress of drug-loaded polymeric micelles into clinical studies","volume":"190","author":"Cabral","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114613_b0170","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.addr.2017.02.003","article-title":"The battle of \u201cnano\u201d paclitaxel","volume":"122","author":"Sofias","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114613_b0175","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.addr.2020.09.009","article-title":"Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval","volume":"156","author":"Hwang","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114613_b0180","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Maeda","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2022.114613_b0185","article-title":"Recent clinical developments of nanomediated drug delivery systems of taxanes for the treatment of","author":"Van Eerden","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2022.114613_b0190","first-page":"1","article-title":"Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug","volume":"6","author":"Pittet","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2022.114613_b0195","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.addr.2013.08.012","article-title":"Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status","volume":"65","author":"Van Der Meel","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114613_b0200","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1021\/acs.bioconjchem.9b00456","article-title":"Insights into active targeting of nanoparticles in drug delivery: advances in clinical studies and design considerations for cancer nanomedicine","volume":"30","author":"Pearce","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2022.114613_b0205","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.nano.2010.05.005","article-title":"Advances in polymeric micelles for drug delivery and tumor targeting","volume":"6","author":"Kedar","year":"2010","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.addr.2022.114613_b0210","doi-asserted-by":"crossref","first-page":"1600160","DOI":"10.1002\/mabi.201600160","article-title":"Physico-chemical strategies to enhance stability and drug retention of polymeric micelles for tumor-targeted drug delivery","volume":"17","author":"Shi","year":"2016","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.addr.2022.114613_b0215","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/sj.bjc.6601856","article-title":"Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer","volume":"90","author":"Danson","year":"2004","journal-title":"Br. J. Can."},{"key":"10.1016\/j.addr.2022.114613_b0220","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/sj.bjc.6602479","article-title":"NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel","volume":"92","author":"Hamaguchi","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2022.114613_b0225","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41416-019-0391-z","article-title":"A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients","volume":"120","author":"Fujiwara","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2022.114613_b0230","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1021\/acsnano.5b00929","article-title":"Complete regression of xenograft tumors upon targeted delivery of paclitaxel via \u220f - \u220f stacking stabilized polymeric micelles","volume":"9","author":"Shi","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2022.114613_b0235","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jconrel.2009.04.019","article-title":"Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin","volume":"138","author":"Kim","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114613_b0240","unstructured":"C.J.F. Rijcken, Tuneable and degradable polymeric micelles for drug delivery: from synthesis to feasibility in vivo, Utrecht University, 2007."},{"key":"10.1016\/j.addr.2022.114613_b0245","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/cas.12153","article-title":"NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin","volume":"104","author":"Takahashi","year":"2013","journal-title":"Cancer Sci."},{"key":"10.1016\/j.addr.2022.114613_b0250","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.biomaterials.2015.02.085","article-title":"Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles","volume":"53","author":"Hu","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114613_b0255","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jconrel.2016.07.012","article-title":"Tailoring the physicochemical properties of core-crosslinked polymeric micelles for pharmaceutical applications","volume":"244","author":"Hu","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114613_b0260","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jpba.2018.08.035","article-title":"A new method for the determination of total and released docetaxel from docetaxel-entrapped core-crosslinked polymeric micelles (CriPec \u00ae) by LC \u2013 MS \/ MS and its clinical application in plasma and tissues in patients with various tumours","volume":"161","author":"Braal","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.addr.2022.114613_b0265","doi-asserted-by":"crossref","unstructured":"C.J. Rijcken, C.J. Snel, R.M. Schiffelers, C.F. Van Nostrum, W.E. Hennink, Hydrolysable core-crosslinked thermosensitive polymeric micelles\u00a0: Synthesis , characterisation and in vivo studies, 28 (2007) 5581\u20135593. 10.1016\/j.biomaterials.2007.08.047.","DOI":"10.1016\/j.biomaterials.2007.08.047"},{"key":"10.1016\/j.addr.2022.114613_b0270","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1002\/anie.201202713","article-title":"Glucocorticoid-loaded core-crosslinked polymeric micelles with tailorable release kinetics for targeted rheumatoid arthritis therapy","volume":"51","author":"Crielaard","year":"2012","journal-title":"Angew. Chemie Int. Ed."},{"key":"10.1016\/j.addr.2022.114613_b0275","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-20-0008","article-title":"Intratumoral comparison of nanoparticle entrapped docetaxel (CPC634) with conventional docetaxel in patients with solid tumors","volume":"26","author":"Atrafi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2022.114613_b0280","doi-asserted-by":"crossref","unstructured":"F. Atrafi, H. Dumez, R.H.J. Mathijssen, C.W. Menke-van der Houven van Oordt, C.J.F. Rijcken, R. Hanssen, F.A.L.M. Eskens, P. Sch\u00f6ffski, A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours, J. Control. Release. 325 (2020) 191\u2013197. 10.1016\/j.jconrel.2020.06.020.","DOI":"10.1016\/j.jconrel.2020.06.020"},{"key":"10.1016\/j.addr.2022.114613_b0285","first-page":"1907574","article-title":"Polymeric nanoparticles with neglectable protein corona","volume":"16","author":"Alberg","year":"2020","journal-title":"Nano Micro Small."},{"key":"10.1016\/j.addr.2022.114613_b0290","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153741","article-title":"Docetaxel skin exposure and micronucleation contributes to skin toxicity caused by cpc634","volume":"13","author":"Atrafi","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.addr.2022.114613_b0295","doi-asserted-by":"crossref","first-page":"7589","DOI":"10.1021\/ma011198q","article-title":"Thermoresponsive polymeric micelles with controlled instability based on hydrolytically sensitive N-isopropylacrylamide copolymers","volume":"34","author":"Neradovic","year":"2001","journal-title":"Macromolecules"},{"key":"10.1016\/j.addr.2022.114613_b0300","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1016\/j.biomaterials.2010.07.005","article-title":"Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin","volume":"31","author":"Talelli","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114613_b0305","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1515\/EJNM.2010.3.1.19","article-title":"Crosslinked micelles with transiently linked drugs - a versatile drug delivery system","volume":"3","author":"Rijcken","year":"2010","journal-title":"Eur. J. Nanomedicine."},{"key":"10.1016\/j.addr.2022.114613_b0310","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2016.09.030","article-title":"High systemic availability of core-crosslinked polymeric micelles after subcutaneous administration","volume":"514","author":"Hu","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114613_b0315","doi-asserted-by":"crossref","unstructured":"D. Neri, C.T. Supuran, Interfering with pH regulation in tumours as a therapeutic strategy, (2011). 10.1038\/nrd3554.","DOI":"10.1038\/nrd3554"},{"key":"10.1016\/j.addr.2022.114613_b0320","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrc1478","article-title":"Why do cancers have high aerobic glycolysis?","volume":"4","author":"Gatenby","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2022.114613_b0325","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0167-8140(84)80077-8","article-title":"The relevance of tumour pH to the treatment of malignant disease","volume":"2","author":"Wike-Hooley","year":"1984","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.addr.2022.114613_b0330","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nantod.2011.02.003","article-title":"Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies","volume":"6","author":"Iversen","year":"2011","journal-title":"Nano Today"},{"key":"10.1016\/j.addr.2022.114613_b0335","unstructured":"W. Gao, J.M. Chan, O.C. Farokhzad, pH-Responsive Nanoparticles for Drug Delivery, (n.d.). 10.1021\/mp100253e."},{"key":"10.1016\/j.addr.2022.114613_b0340","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1021\/acs.bioconjchem.2c00310","article-title":"A new class of tunable acid-sensitive linkers for native drug release based on the trityl protecting group","volume":"33","author":"Timmers","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2022.114613_b0345","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0168-3659(02)00348-6","article-title":"HPMA copolymers with pH-controlled release of doxorubicin: In vitro cytotoxicity and in vivo antitumor activity","volume":"87","author":"Ulbrich","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114613_b0350","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2014.12.023","article-title":"A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles","volume":"205","author":"Hu","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114613_b0355","article-title":"Profiling target engagement and cellular uptake of cRGD-decorated clinical-stage core-crosslinked polymeric micelles","author":"De Lorenzi","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.addr.2022.114613_b0360","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jconrel.2020.09.046","article-title":"Optical imaging of the whole-body to cellular biodistribution of clinical-stage PEG-b-pHPMA-based core-crosslinked polymeric micelles","volume":"328","author":"Biancacci","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114613_b0365","doi-asserted-by":"crossref","first-page":"2201043","DOI":"10.1002\/adma.202201043","article-title":"Menke-van der Houven van Oordt, PET-CT imaging of polymeric nanoparticle tumor accumulation in patients","volume":"34","author":"Miedema","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2022.114613_b0370","doi-asserted-by":"crossref","first-page":"9011","DOI":"10.1039\/D0SC03477K","article-title":"TMTHSI, a superior 7-membered ring alkyne containing reagent for strain-promoted azide-alkyne cycloaddition reactions","volume":"11","author":"Weterings","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.addr.2022.114613_b0375","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1021\/bc3000595","article-title":"Molecular characterization of multivalent bioconjugates by size_exclusion chromatography (SEC) with multi-angle laser light scattering (MALS)","volume":"23","author":"Pollock","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2022.114613_b0380","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.1021\/ac3007768","article-title":"Polydispersity characterization of lipid nanoparticles for siRNA delivery using multiple detection size-exclusion chromatography","volume":"84","author":"Zhang","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.addr.2022.114613_b0385","doi-asserted-by":"crossref","first-page":"e2000212","DOI":"10.1002\/biot.202000212","article-title":"Lyophilization stabilizes clinical-stage core-crosslinked polymeric micelles to overcome cold chain supply challenges","volume":"16","author":"Ojha","year":"2021","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.addr.2022.114613_b0390","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jconrel.2009.08.011","article-title":"Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel","volume":"140","author":"Danhier","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114613_b0395","first-page":"1555","article-title":"Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging","volume":"6","author":"Cai","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2022.114613_b0400","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2018.01.020","article-title":"Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery","volume":"129","author":"Schnittert","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114613_b0405","doi-asserted-by":"crossref","first-page":"2100370","DOI":"10.1002\/advs.202100370","article-title":"Cyclic Arginine\u2013Glycine\u2013Aspartate-Decorated Lipid Nanoparticle Targeting toward Inflammatory Lesions Involves Hitchhiking with Phagocytes","volume":"8","author":"Sofias","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2022.114613_b0410","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","article-title":"Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology","volume":"73","author":"Prabhakar","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2022.114613_b0415","doi-asserted-by":"crossref","first-page":"22849","DOI":"10.1039\/C9NR08261A","article-title":"The vacuolization of macrophages induced by large amounts of inorganic nanoparticle uptake to enhance the immune response","volume":"11","author":"Cheng","year":"2019","journal-title":"Nanoscale."},{"key":"10.1016\/j.addr.2022.114613_b0420","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00003088-199936020-00002","article-title":"Clinical pharmacokinetics of docetaxel","volume":"36","author":"Clarke","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2022.114613_b0425","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ejca.2005.02.016","article-title":"Docetaxel administration schedule: From fever to tears? A review of randomised studies","volume":"41","author":"Engels","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2022.114613_b0430","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ctrv.2015.04.012","article-title":"Inter-patient variability in docetaxel pharmacokinetics: A review","volume":"41","author":"Nieuweboer","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.addr.2022.114613_b0435","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-15-2548","article-title":"Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors","volume":"22","author":"Von Hoff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2022.114613_b0440","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s10637-021-01081-x","article-title":"First-in-human, phase I\/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies","volume":"39","author":"Piha-Paul","year":"2021","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.addr.2022.114613_b0445","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1021\/acsnano.8b07865","article-title":"Dexamethasone increases cisplatin-loaded nanocarrier delivery and efficacy in metastatic breast cancer by normalizing the tumor microenvironment","volume":"13","author":"Martin","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2022.114613_b0450","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41563-020-0755-z","article-title":"The dose threshold for nanoparticle tumour delivery","volume":"19","author":"Ouyang","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2022.114613_b0455","article-title":"Taxotere summary of product characteristics","author":"Longhitano","year":"2008","journal-title":"Eur. Med. Agency."},{"key":"10.1016\/j.addr.2022.114613_b0460","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1998.16.1.187","article-title":"Population pharmacokinetics\/pharmacodynamics of docetaxel in phase ii studies in patients with cancer","volume":"16","author":"Bruno","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114613_b0465","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1349-7006.2006.00166.x","article-title":"Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients","volume":"97","author":"Minami","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.addr.2022.114613_b0470","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2022.114613_b0475","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41551-019-0498-9","article-title":"Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips","volume":"4","author":"Herland","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.addr.2022.114613_b0480","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41569-020-00439-7","article-title":"The COVID-19 pandemic: a catalyst to improve clinical trials","volume":"17","author":"Gaba","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.addr.2022.114613_b0485","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41591-022-01775-6","article-title":"Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition","volume":"28","author":"Li","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2022.114613_b0490","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41565-019-0567-y","article-title":"Smart cancer nanomedicine","volume":"14","author":"van Der Meel","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2022.114613_b0495","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/d41573-022-00030-4","article-title":"Challenges and opportunities in the PD1\/PDL1 inhibitor clinical trial landscape","volume":"21","author":"Upadhaya","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2022.114613_b0500","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.biomaterials.2012.09.064","article-title":"Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy","volume":"34","author":"Talelli","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114613_b0505","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114613_b0510","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2022.114613_b0515","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114613_b0520","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41523-022-00386-1","article-title":"Immunotherapy for early triple negative breast cancer: research agenda for the next decade","volume":"8","author":"Tarantino","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.addr.2022.114613_b0525","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.addr.2022.114613_b0530","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2022.114613_b0535","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, N","volume":"379","author":"Schmid","year":"2018","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114613_b0540","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1021\/acs.accounts.9b00148","article-title":"Combining nanomedicine and immunotherapy","volume":"52","author":"Shi","year":"2019","journal-title":"Acc. Chem. Res."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22005038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22005038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:35:49Z","timestamp":1759210549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X22005038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":108,"alternative-id":["S0169409X22005038"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2022.114613","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, development and clinical translation of CriPec\u00ae-based core-crosslinked polymeric micelles","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2022.114613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114613"}}